Market Overview

UPDATE: Canaccord Genuity Raises PT to $115 on Edwards Lifesciences Ahead of Q4 Results

Share:
Related EW
Goldman's New Pair Trade Opportunity
Earnings Scheduled For July 28, 2015
Mitral Valve Space Heats Up With Abbott Deals (Seeking Alpha)

Canaccord Genuity reiterated its Buy rating on Edwards Lifesciences (NYSE: EW) and raised the price target from $109.00 to $115.00.

Canaccord Genuity noted, "We expect strong sequential US sales growth in Q4 (44%E), driven by TF TAVI uptake in Cohort B patients and initial uptake in Cohort A-high risk patients. While we expect tepid growth in Europe (4% Y/Y) - reflecting austerity measures, pricing pressure, and new competitive valves – we think Q4 results will show meaningful improvement from the weak Q3, as we think registry data in H2/12 boded well for SAPIEN vs. CoreValve and also think EW's share of transaortic market (TAo) improved."

Edwards Lifesciences closed at $93.41 on Friday.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

Get Benzinga's Newsletters